257 related articles for article (PubMed ID: 33999716)
21. Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer.
Rao DY; Huang DF; Si MY; Lu H; Tang ZX; Zhang ZX
Front Immunol; 2023; 14():1142539. PubMed ID: 37122754
[TBL] [Abstract][Full Text] [Related]
22. Small RNAs and non-small cell lung cancer.
Tong AW
Curr Mol Med; 2006 May; 6(3):339-49. PubMed ID: 16712479
[TBL] [Abstract][Full Text] [Related]
23. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.
Liu HY; Yu X; Liu H; Wu D; She JX
Sci Rep; 2016 Jul; 6():30346. PubMed ID: 27456457
[TBL] [Abstract][Full Text] [Related]
24. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
[TBL] [Abstract][Full Text] [Related]
25. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
26. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Okamoto K; Okamoto I; Hatashita E; Kuwata K; Yamaguchi H; Kita A; Yamanaka K; Ono M; Nakagawa K
Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159
[TBL] [Abstract][Full Text] [Related]
27. Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Nakagawa N; Miyake N; Ochi N; Yamane H; Takeyama M; Nagasaki Y; Ikeda T; Yokota E; Fukazawa T; Nakanishi H; Harada D; Kiura K; Takigawa N
Exp Cell Res; 2021 Dec; 409(2):112940. PubMed ID: 34808132
[TBL] [Abstract][Full Text] [Related]
28. Milk exosomes - Natural nanoparticles for siRNA delivery.
Aqil F; Munagala R; Jeyabalan J; Agrawal AK; Kyakulaga AH; Wilcher SA; Gupta RC
Cancer Lett; 2019 May; 449():186-195. PubMed ID: 30771430
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
31. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
32. Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells.
Zhang Z; Jiang G; Yang F; Wang J
Cancer Biol Ther; 2006 Nov; 5(11):1481-6. PubMed ID: 17172815
[TBL] [Abstract][Full Text] [Related]
33. MDM2 knockdown mediated by a triazine-modified dendrimer in the treatment of non-small cell lung cancer.
Huang Q; Li L; Li L; Chen H; Dang Y; Zhang J; Shao N; Chang H; Zhou Z; Liu C; He B; Wei H; Xiao J
Oncotarget; 2016 Jul; 7(28):44013-44022. PubMed ID: 27259273
[TBL] [Abstract][Full Text] [Related]
34. Specific inhibition of tumor cells by oncogenic EGFR specific silencing by RNA interference.
Takahashi M; Chiyo T; Okada T; Hohjoh H
PLoS One; 2013; 8(8):e73214. PubMed ID: 23951344
[TBL] [Abstract][Full Text] [Related]
35. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
37. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
[TBL] [Abstract][Full Text] [Related]
38. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
39. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
[TBL] [Abstract][Full Text] [Related]
40. [Immunotherapy in Epidermal Growth Factor Receptor-mutant
Non-small Cell Lung Cancer].
Wang X; Zhong D
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):541-545. PubMed ID: 31451147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
